Comparison of the health assessment questionnaire disability index and the short form 36 physical functioning subscale using Rasch analysis: Comment on the article by Taylor and McPherson

2008 ◽  
Vol 59 (4) ◽  
pp. 598-599 ◽  
Author(s):  
James F. Fries ◽  
Bonnie Bruce ◽  
Matthias Rose
Keyword(s):  
Physical Functioning ◽  
Health Assessment Questionnaire ◽  
Rasch Analysis ◽  
Short Form ◽  
Health Assessment ◽  
Short Form 36 ◽  
Functioning Subscale ◽  
Physical Functioning Subscale ◽  
Assessment Questionnaire ◽  
Questionnaire Disability

Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase

Rheumatology ◽  
2019 ◽  
Vol 58 (8) ◽  
pp. 1422-1431 ◽  
Author(s):  
N Lawrence Edwards ◽  
Jasvinder A Singh ◽  
Orrin Troum ◽  
Anthony E Yeo ◽  
Peter E Lipsky
Keyword(s):  
Health Assessment Questionnaire ◽  
Global Assessment ◽  
Short Form ◽  
Bodily Pain ◽  
Health Assessment ◽  
Serum Urate ◽  
Patient Global Assessment ◽  
Short Form 36 ◽  
Assessment Questionnaire ◽  
Questionnaire Disability

Abstract Objective To determine the characteristics and response to pegloticase of patients with chronic refractory gout with and without clinically apparent tophi. Methods Results from two randomized controlled trials of pegloticase in patients with chronic refractory gout with clinically apparent tophi or without tophi were used to assess baseline and on-treatment between-group differences. Results Patients with tophi were significantly older than those without tophi, had a significantly longer duration of disease, higher numbers of tender and swollen joints, higher Patient Global Assessment scores and Health Assessment Questionnaire-Disability Index scores, and lower Arthritis-Specific Health Index scores. Patients with tophaceous gout also had significantly lower scores for physical functioning, role physical, social functioning, and the physical component summary scores of the Short Form 36 vs patients without tophi. In addition, subjects with clinically apparent tophi had a significantly lower mean estimated glomerular filtration rate. Pegloticase treatment of tophaceous patients caused significant reductions in serum urate, flares, Patient Global Assessment, tender joints, swollen joints, Health Assessment Questionnaire-Disability Index, visual analogue scale pain and Short Form 36 Bodily Pain, whereas patients without tophi had significant improvement in serum urate, flares, Patient Global Assessment, tender joints, and Short Form 36 Bodily Pain, but not swollen joints, Health Assessment Questionnaire-Disability Index functional score or pain visual analogue scale. Treatment with pegloticase had no effect on estimated glomerular filtration rate despite significant lowering of the urinary uric acid: creatinine ratio. Conclusion Patients with chronic refractory gout and clinically apparent tophi have more severe disease as well as reduced renal function. Both groups experienced significant clinical benefit with pegloticase treatment, although no change in renal function was noted.

scholarly journals Validating and Assessing the Sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in Patients with Early Aggressive Rheumatoid Arthritis

2009 ◽  
Vol 36 (6) ◽  
pp. 1150-1157 ◽  
Author(s):  
SOGOL S. AMJADI ◽  
PAUL M. MARANIAN ◽  
HAROLD E. PAULUS ◽  
ROBERT M. KAPLAN ◽  
VEENA K. RANGANATH ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Construct Validity ◽  
Health Assessment Questionnaire ◽  
Short Form ◽  
Health Assessment ◽  
Correlation Coefficients ◽  
Patient Reported ◽  
Clinical Measures ◽  
Assessment Questionnaire ◽  
Questionnaire Disability

Objective.New methodologies allow the scores for the Health Assessment Questionnaire-Disability Index (HAQ-DI) to be translated into preferences/utility scores. We evaluated the construct validity of the HAQ-DI-derived Short Form-6D (SF-6D) score and assessed its responsiveness to change over 6- and 12-month followup periods in patients with early aggressive rheumatoid arthritis (RA).Methods.Patients (n = 277) participating in an RA observational study completed self-reported measures of symptoms and the HAQ-DI at baseline and at 6 and 12 months. Total Sharp scores, C-reactive protein, and erythrocyte sedimentation rate were assessed along with clinical data. Construct validity was assessed by examining the association between SF-6D score and patient-reported and clinical measures using Spearman correlation coefficients. The responsiveness of SF-6D to change was assessed using patient and physician assessments of the disease as clinical anchors. The magnitude of responsiveness was calculated using SF-6D effect size (ES).Result.Mean SF-6D scores were 0.690, 0.720, and 0.723 at baseline and 6 and 12-month followup, respectively. Baseline patient-reported measures had moderate to high correlations with baseline SF-6D (r = 0.43 to 0.52); whereas clinical measures had negligible to low correlations with SF-6D (r = 0.001 to 0.32). ES was moderate for the groups that were deemed to have improved (ES 0.63–0.75) but negligible to small for those that did not (ES 0.13–0.46).Conclusion.Our data support the validity and responsiveness of the HAQ-DI derived SF-6D score in an early RA cohort. These results support the use of the HAQ-DI derived SF-6D in RA cohorts and clinical trials lacking preference-based measures.

Sign in / Sign up

Export Citation Format

Share Document